Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Desh Rakshak Aushdhalaya Ltd. operates in the Indian pharmaceutical sector, focusing on specialty and generic drug manufacturing. The company differentiates itself through a robust portfolio of affordable healthcare solutions, primarily targeting the domestic market with a growing presence in emerging markets.
Desh Rakshak Aushdhalaya generates revenue primarily through the production and sale of generic and specialty pharmaceuticals, leveraging its cost-effective manufacturing processes. The company benefits from strong pricing power in the domestic market due to its established brand reputation and extensive distribution network.
Changes in regulatory policies affecting drug approvals in India
Market share gains in the generic drug segment
Fluctuations in raw material costs, particularly APIs
Partnerships or contracts with larger pharmaceutical companies
Regulatory changes that could impact drug pricing and approvals
Technological advancements in drug manufacturing that could disrupt traditional processes
Intensifying competition from both domestic and international generic manufacturers
Potential entry of large multinational pharmaceutical companies into the Indian market
Low return on equity (4.6%) indicating potential inefficiencies in capital utilization
Negative free cash flow could limit operational flexibility
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but consumer spending on healthcare can be affected by broader economic conditions.
Interest rates impact the company's cost of capital and financing for expansion, but given the low debt levels, the direct impact is minimal. Higher rates could also dampen consumer spending on healthcare products.
minimal - The company has a low debt-to-equity ratio of 0.21, indicating limited reliance on external financing.
value - Investors may be drawn to the stock due to its low valuation metrics and potential for recovery in earnings.
moderate - The stock has shown significant volatility with a 1-year return of -55.5%, indicating potential for both risk and reward.
